My career in the world of investing began at an early age, fueled by the potential for profits, I first began investing at the age of 11 with the help of my father. I first began picking stocks by looking at what was going to logically make money, and I had great success. Nowadays, I specialize in quantitative and fundamental analysis for stocks, particularly in small to mid-cap stocks. I adopt a value-investing strategy with one of my key tenets being to never overpay for a stock, this mitigates risk by av ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38492 Kiniksa Pharmaceuticals International, plc (Exact Name of Registrant as Specified in Its Charter) E ...

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to a loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -30.30%. A quarter ago, it was expected that this company would post earnings of $0.18 per share when it actually produced earnings of $0.23, delivering a surprise of +27.78%.Over the last ...

Kiniksa Pharmaceuticals International (NasdaqGS:KNSA) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsJohn Paolini - CMOMary Kate - Head of Art AdvisorySanj Patel - Chairman and CEOMark Ragosa - CFOJonathan Kirshenbaum - Associate Director of Investor RelationsRoss Moat - Chief Corporate and Commercial OfficerConference Call ParticipantsDavid Nierengarten - Senior Biotechnology Equity AnalystRoger Song - Senior Equity Research AnalystNick Larissa - Vice President and Biotech Equity Re ...

Kiniksa Pharmaceuticals International (NasdaqGS:KNSA) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Speaker2Thank you for standing by and welcome to the Kiniksa Pharmaceuticals Third Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you'll need to press star 11 on your telephone. If your question has been answered and you'd like to remove you ...

Third Quarter 2025 Financial Results and Recent Portfolio Execution OCTOBER 28, 2025 Agenda 2 Forward Looking Statements This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements with respect to Kiniksa Pharmaceuticals International, plc (and its consolidated subsidiaries, collectively, unless context otherwise requires, "Kiniksa," "we," "us" or "our"). In some cases, you can identify forward looking statements by terms ...

Exhibit 99.1 Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution – ARCALYST (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth – – Conference call and webcast scheduled for 8:30 am ET today – LONDON – October 28, 2025 – Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardio ...

– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 - $675 million –– KPL-387 granted Orphan Drug Designation for the treatment of pericarditis – – Cash balance increased by $44.3 million in Q3 2025 to $352.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), ...

LONDON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 28, 2025 at 8:30 a.m. Eastern Time to report its third quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upo ...

公司核心事件 - Kiniksa Pharmaceuticals 宣布其候选药物 KPL-387 获得美国FDA授予的孤儿药认定，用于治疗心包炎（包括复发性心包炎）[1] - KPL-387 是一种独立开发的、完全人源化的免疫球蛋白IgG2单克隆抗体，可与人类白细胞介素-1受体1结合，抑制细胞因子IL-1α和IL-1β的信号传导活性[1][5] 药物开发进展与预期 - KPL-387 2/3期复发性心包炎试验的2期剂量探索部分数据预计将在2026年下半年公布[2] - 公司认为KPL-387有潜力通过每月一次皮下自我注射的液体剂型给药，为患者提供额外的治疗选择[2][5] 孤儿药认定的意义 - 美国FDA授予孤儿药认定的标准是所治疗的罕见病在美国患病人数少于20万[3] - 获得孤儿药认定可使公司享有财务激励，包括临床试验费用的资助机会、税收优惠和用户费用减免[3] - 孤儿药认定还豁免了该药物在该适应症中进行儿科研究的要求[3] 公司战略与业务重点 - Kiniksa是一家生物制药公司，致力于发现、获取、开发和商业化针对未满足医疗需求的疾病的新型疗法[4] - 公司的业务重点集中在心血管适应症领域[1][4] - 公司的产品组合基于强大的生物学原理或经过验证的作用机制，并具有差异化的潜力[4]